Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis

Next Previous
Trial Profile

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpibectir (Primary) ; Ethionamide (Primary) ; Isoniazid
  • Indications Pulmonary tuberculosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BETO

Most Recent Events

  • 27 Aug 2025 According to BioVersys AG media release, company announced that the European Medicines Agency Committee for Orphan Medicinal Products (EMA COMP) has granted orphan designation for the combination of alpibectir and ethionamide (AlpE) for the treatment of tuberculosis (TB).
  • 16 Oct 2024 Status changed from recruiting to completed as per a BioVersys media release.
  • 12 Dec 2023 According to a BioVersys AG media release, the TRIC-TB Project continues to receive funding from the EU IMI-JU2 programme under the AMR Accelerator umbrella and from the European & Developing Countries Clinical Trials Partnership (EDCTP2 programme) for the bEto-TB Project (Phase 2a).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top